Journal
FRONTIERS IN IMMUNOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.602395
Keywords
cytokine serum profile; biomarker; coronavirus disease-2019 prognosis; respiratory syndrome coronavirus 2; cytokine storm; interleukin-6; interleukin-8
Categories
Funding
- Research Funds from Chinese Academy of Medical Sciences [2016-I2M-1-005, 2019XK310002]
- National Science funds [2015ZX09102023, NSFC 91542201, 81590765, 31670883, 31870912, 81802870, 2017YFA0506200]
- US National Institute of Health funds [AI069120, AI056154, AI140718, AI028697]
- UCLA AIDS Institute
- UCLA David Geffen School of Medicine - Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [3332018131]
- Science funds from Jiangsu Province [BK20170407, BK20151253]
- The Innovative and Entrepreneurial Team grant (2018-2021) from Jiangsu Province
- Chinese Postdoctoral Science Foundation [2019M650564]
- CAMS Innovation Fund for Medical Sciences (CIFMS) [2019I2M-1-003]
- Innovative and Entrepreneurial Doctor grant (2020-2022) from Jiangsu Province
- Natural Science Foundation of Hubei Province Grant [2016CFB154]
- Scientific and Technological Project of Shiyan City of Hubei Province [18Y26]
- Key Project of Jiangsu Provincial Health Commission [K2019021]
Ask authors/readers for more resources
The study identified IL-8 as a biomarker to predict disease severity and prognosis of COVID-19 patients, showing that IL-8 is more distinct for mild cases compared to IL-6.
The widespread prevalence of coronavirus disease-2019 (COVID-19) which is caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has resulted in a severe global public health emergency. However, there are no sensitive biomarkers to predict the disease prognosis of COVID-19 patients. Here, we have identified interleukin-8 (IL-8) as a biomarker candidate to predict different disease severity and prognosis of COVID-19 patients. While serum IL-6 become obviously elevated in severe COVID-19 patients, serum IL-8 was easily detectible in COVID-19 patients with mild syndromes. Furthermore, lL-8 levels correlated better than IL-6 levels with the overall clinical disease scores at different stages of the same COVID-19 patients. Thus, our studies suggest that IL-6 and IL-8 can be respectively used as biomarkers for severe COVID-19 patients and for COVID-19 disease prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
